Across the eighteen Dubai and Abu Dhabi clinic pages we read on 8 September 2026, under-eye filler is advertised from as little as AED 800, most often quoted per syringe from around AED 1,200, and framed as the fastest thing in aesthetics. Fifteen to thirty minutes, and back at your desk.
Not one of those eighteen pages tells you what it costs to take it out again.
That number exists, because dissolving is openly sold in Dubai as its own service, and on the pages that sell it the published figures run from AED 200 per millilitre to AED 700 to 2,000 per session. It is simply never printed next to the treatment. You are quoted for putting it in and never for changing your mind.
Which is a small omission standing in front of a much larger one. Almost every page selling this treatment is selling it for dark circles, and dark circles are not one thing. They are at least four separate problems that happen to produce the same complaint in a mirror, and filler addresses one of them. Get that wrong and the best case is that you have paid for nothing. The under-eye also has the thinnest skin on the body over it, which is why being wrong there shows, for reasons of anatomy that take a paragraph to explain and that no clinic page we read explains at all.
Every AED figure here is an indicative 2026 market estimate read off a published UAE menu on a stated date, not a measured average. Two of those eighteen pages state whether VAT is included. The rest are silent, so we cannot tell you either way.
Four different problems, one complaint
Start here, before any price. If you cannot say which of these is casting the shadow, you are not ready to be quoted.
FOUR DIFFERENT PROBLEMS, ONE COMPLAINT
Hollowing
The only one filler treats
- What it is
- Bone recession and fat loss along the orbital rim, casting a shadow
- How to spot it
- Dim the room, or use a light directly overhead. A structural shadow deepens
- What helps
- Filler, or fat grafting. Often the midcheek rather than the trough itself
Pigmentation
Filler does not lighten it
- What it is
- Melanin in the eyelid skin. Six per cent of cases in one 100-patient classification study
- How to spot it
- Bright light, and gently stretch the lower lid skin. Pigment stays visible
- What helps
- Topicals, peels and lasers. Filler may soften a shadow, never a colour
Vessels showing through
The commonest type in that study
- What it is
- The dark orbicularis muscle and veins seen through skin under one millimetre thick
- How common
- Fifty-one per cent of the 100 patients in that same 2020 classification
- What helps
- Not filler placed superficially, which risks a blue-grey tint of its own
The bag itself
Usually a surgical answer
- What it is
- Orbital fat pushing forward through a weakened septum
- How to spot it
- Look up without moving your head. The bulge becomes more obvious
- What helps
- Lower eyelid surgery. Filler in front of a bag can make it read heavier
The two lighting tricks in that figure come from a 2024 assessment framework in the Aesthetic Surgery Journal, and they work in a bathroom. Overhead light exaggerates a structural hollow and flattens pigment. Bright direct light does the opposite. Stretching the lid skin separates colour from shadow, because colour survives the stretch and shadow does not. Looking up without moving your head brings a fat pad forward.
That framework surveyed thirty-nine practitioners across eighteen countries, almost all with more than ten years in aesthetic medicine, and reported that only 26 per cent used any tear trough classification system at all. Three quarters of very experienced injectors are working without one. Its conclusion is the most commercially inconvenient sentence in this whole topic, and it is worth reading twice: careful step-by-step assessment can identify patients whose dark circles improve without injecting filler into the tear trough at all, most often by treating the midcheek instead. All thirty-nine agreed midcheek volume was critical. The paper was sponsored by a filler manufacturer, which makes that conclusion more interesting rather than less.
There is one more line in that classification with local relevance. It describes a congenital pattern where the whole maxillary orbital rim is deficient, producing large prominent eyes with visible white below the iris, and notes it is common in patients of Southern Asian, Middle Eastern, Turkish and Iranian descent. If your under-eyes looked like this in your twenties rather than arriving in your forties, you are a different case from the one the marketing is written for. We cover the pigment route separately in our piece on pigmentation on Gulf skin.
Why the under-eye is unforgiving
The skin of the eyelid is the thinnest on the human body, under a millimetre. Anything placed beneath it can be seen through it, which is the whole reason a superficial deposit reads blue-grey rather than invisible.
Beneath that sits a structural problem. The orbital septum holds the fat pads back, and when it weakens they bulge forward, which is what an eye bag is. Filler placed in front of a bag does not remove the bag. It fills the ditch behind it and can leave the whole area reading heavier.
Then the lymphatics, which is the fact almost nobody is told. Lymphatic vessels around the eye and midface have fewer valves than those in the limbs, so they are more prone to obstruction, and compromised drainage in the lower lid can lead to exactly the prolonged puffiness people complain about afterwards. There is a fascial layer, the malar septum, that behaves as a relatively impermeable barrier, and filler placed superficial to it can reinforce that barrier and dam the fluid behind it.
And the part that should end the "it just sits on the bone" reassurance: anatomists have reported that there is no dissectible plane beneath the orbicularis muscle in the infraorbital hollow, so injections there may be best described as sitting within the muscle. Imaging studies of injections aimed at the bone found the material did not stay put with much precision. Even when the injector aims for the periosteum, the gel does not necessarily arrive there.
Those anatomical descriptions come from a 2023 review that was funded by a filler manufacturer, with most authors declaring industry relationships. We are using it because it is the most detailed account available and because none of what it says about anatomy favours the sponsor.
The assessment is the treatment decision. Everything after it is execution.
What actually goes wrong, in order of likelihood
The pooled data is reassuring, and the ordinary complications are still common. A 2024 systematic review and meta-analysis brought together 31 reports covering 2,556 patients and found a pooled satisfaction rate of 91 per cent, which the article is not going to argue with. Alongside it:
POOLED FROM 2,556 PATIENTS
Roughly one patient in five gets swelling, and that is the honest headline of this treatment. Most of it is the swelling of the first weekend. A smaller share is not. A 2023 ultrasound study of seventeen patients found the onset of malar oedema after periorbital filler ranged from immediately to three years later, with filler material sitting inside the fascia in 23 of 26 eyes, and venous flow restoring once it was removed. A separate small series of fifteen women with malar oedema recorded that all of them had already been treated with hyaluronidase, and that it was ineffective in every case.
The blue-grey tint is uncommon at under one per cent, but it does not fade on any useful timescale. The literature treats dissolving as the answer rather than patience.
Longevity is where the sales pitch and the evidence separate most cleanly. Dubai pages claim six to twelve months. A retrospective study of 155 patients found the effect still measurably present at eighteen months, with no significant difference between the six, twelve and eighteen month follow-ups. And a small cross-sectional MRI study of fourteen patients with documented filler histories found the volume it could measure exceeded the volume that had been injected, at a ratio of about one to 2.8, which the authors suggest may explain post-injection swelling. Fourteen people is not much to build on, so treat that ratio as a signal rather than a finding.
The practical reframing is this. "Six to twelve months" is roughly how long the effect the clinic sold you is judged to last. It is not a date on which the material leaves. So the question at a top-up appointment is not how long the new syringe will last. It is what is still in there from last time.
The rare one, with its actual denominators
This is where writing about aesthetics usually goes wrong in one of two directions, and both are a disservice.
The best real-world numbers come from a 2021 study in JAMA Dermatology in which 370 board-certified dermatologists reported on 1.7 million syringes across every facial site, not the tear trough alone.
THE NUMBERS BEHIND THE WORD RARE
Injected with a needle
1 occlusion per 6,410 syringes
- Source
- 370 dermatologists reporting 1.7 million one-millilitre syringes across all facial sites, JAMA Dermatology 2021
- Design
- Retrospective self-report. The authors name recall bias and under-reporting as limitations
Injected with a cannula
1 occlusion per 40,882 syringes
- The difference
- 77.1 per cent lower odds than a needle, p below 0.001
- The caveat
- A cannula is not risk-free. Arterial penetration remains possible
How those occlusions ended
85 per cent with no long-term consequence
- Who saw one
- 106 of the 370 dermatologists, 28.6 per cent, reported at least one
- Ocular events
- Three across the entire 1.7 million syringes
Vision loss
Published estimate 1 in 100,000 injections
- The figure
- From a review of 511 published cases up to March 2023
- Why to distrust it
- A UK expert panel reviewed that figure and agreed no specific number should be quoted, only the word rare
If it does happen
68.2 per cent never recovered any vision
- Of 318 cases with outcome data
- 6.0 per cent recovered fully, 25.8 per cent partially
- The hard part
- No treatment was significantly associated with visual improvement
Read those five cards together rather than separately. Occlusion of any kind is uncommon and usually resolves without lasting harm. Vision loss is rarer again, rare enough that a panel of ophthalmologists, oculoplastic surgeons, retina specialists and aesthetic clinicians looked at the one in a hundred thousand estimate and agreed it should not be quoted at all, because nobody knows how many injections are given or how many events go unreported. And in the cases that do reach the literature, two in three people never got their sight back, and nothing anyone tried was statistically shown to change that.
Two things must be said plainly here. The first is that those published cases are a numerator without a denominator, drawn from a literature that publishes the severe and the unusual. The second is more useful to you: the tear trough does not appear in the top-risk site list of any of the three world-literature reviews of filler blindness. Across reviews in 2015, 2019 and 2024, the sites that dominate are the nose at 25.5 to 56.3 per cent of cases, the glabella between the brows at 19.0 to 38.8 per cent, and the forehead at 12.2 to 27.7 per cent. The tear trough is not on that list.
So the honest position is narrower than either the scare or the reassurance. The under-eye is anatomically wired into the eye's blood supply, and in a study of 158 hemifaces from Chinese cadavers the artery running through the tear trough came directly off the ophthalmic artery in 57.6 per cent of cases. It is a one-step connection in most people. The same literature notes that the orbital rim itself carries no major arteries in most people, so this is a question of plane and pressure rather than a region that is simply dangerous. But it is not among the sites that dominate the published blindness cases, and its commonest real-world failures are cosmetic and stubborn rather than catastrophic.
What that adds up to is a case about plane and pressure and who is holding the instrument, rather than a reason to avoid the treatment.
The question worth asking
There is a drug that dissolves hyaluronic acid filler on demand. It is called hyaluronidase, and it is the first thing a clinician reaches for when a filler blocks a blood vessel in skin. The literature reports better outcomes the earlier it is given, and for skin ischaemia rather than for the eye.
It is not a rescue for blindness, and any clinic implying otherwise is wrong. In the published vision-loss cases it was used subcutaneously in 70.1 per cent of them, and no treatment was significantly associated with improvement. Injected behind the eye it was used in 12.6 per cent of cases and vision improved in 5.3 per cent. The UK panel does not recommend that route at all, because of the risk of perforating the eye.
The reason to ask about it anyway is that a clinic that keeps it on the premises is a clinic that has thought about the thing going wrong. In 2026 a UK multidisciplinary panel published consensus guidelines on managing filler-induced vision loss, and reached unanimous agreement that injectors should have an emergency kit readily available. Their list is short: timolol eye drops, a paper bag, aspirin 300 mg, and hyaluronidase, at least 7,500 international units, if the clinician is trained in its use. Their operational instruction is transfer to the nearest emergency department without delay. The kit is what a clinician uses on the way, not instead of going.
Now the part that matters here. We downloaded both UAE standards and searched their full text. The words hyaluronidase, occlusion, necrosis, blind, embolism and antidote appear zero times in either document. Dubai's requires a facility to have "the necessary personnel, equipment and procedures to handle medical and other emergencies", and Abu Dhabi's requires "immediate back-up once an emergency occurs". Neither names a drug, a quantity, a time target or a protocol.
That is not a claim that clinics here are unprepared, and it is not a claim that anyone is breaking a rule. A broad requirement to handle emergencies may well be read as covering the drug. It is a narrower and more useful point: the single most checkable safety question in this treatment has no published answer in either regulator's text, so the only way to find out is to ask. Do you keep hyaluronidase on site, and how much. The 7,500 IU figure is a British recommendation, not an Emirati rule, but it gives you something to hold the answer against.
We could not establish, from any primary UAE source, who may hold hyaluronidase or in what quantity, and we are not going to guess. Every clinical source treats it as a prescription medicine, and Dubai's rule puts prescription-only injectables in a physician's hands, but the standard does not name this drug.
Ask whether it is in the building today, and how much of it there is.
Who is allowed to inject near your eye, and it depends which emirate
DUBAI AND ABU DHABI DIFFER
Dubai, dermatologist or plastic surgeon
Yes, no extra certificate required
- The rule
- DHA Standards for Non-Surgical Cosmetic Procedures v2.1, Appendix 1, the face fillers row
- Worth noting
- Nose filler in Dubai is restricted to these two specialties alone. The eye area is not
Dubai, other physicians and GPs
Yes, with training and privileging
- The route
- Two years post-qualification experience, a one-year mentorship, an in-person certificate, committee privileging
- The gap
- The standard sets no site-specific requirement for the eye area, and never uses the words tear trough
Dubai, nurses and beauty therapists
No
- The rule
- Fillers are prescription-only and may only be administered by a trained and privileged licensed physician, or by an orthodontic, prosthodontic or maxillofacial specialist dentist
- Appendix 1
- Marks nurse, physiotherapist, massage therapist and beauty therapist as not permitted for face fillers
Abu Dhabi, GPs and specialty dentists
Face only, excluding the nose and eyes
- The rule
- DoH Non-Surgical Cosmetics Standard 2024, the dermal fillers row and the legend to its privileging table
- What it means
- A general practitioner or a specialty dentist may not treat the eye area in Abu Dhabi at all
- Not restricted this way
- Dermatologists, plastic surgeons and ophthalmic plastic and reconstructive surgeons. A specialised physician is limited instead to the anatomy of their own licensed title
Abu Dhabi, a right you probably do not know you have
Ask for the licence title
- Clause 4.1.3.1
- The professional must tell you their licence title, which procedures they are privileged for, and their role in the procedure
- Both emirates
- Practitioners may not advertise a title different from the one on their licence
Dubai's standard is not loose. Fillers are classified as a prescription-only medicine and, in the standard's own words, shall only be administered by a trained and privileged licensed physician, in a licensed facility with a supervising dermatologist or plastic surgeon on the books. The same document separately permits three kinds of specialist dentist, orthodontic, prosthodontic and maxillofacial, to perform filler procedures. What it does not do is treat the eye area as its own thing. It carves out the nose, restricting nose filler to dermatologists and plastic surgeons alone, and it has no equivalent carve-out for the periorbital region. The words tear trough, under eye and periorbital do not appear anywhere in its 49 pages.
Abu Dhabi does carve out the eye. In the dermal fillers row of its privileging table, general practitioners and specialty dentists are marked as permitted on the face excluding the nose and eyes, so neither may treat the under-eye there at all. Dermatologists, plastic surgeons and ophthalmic plastic and reconstructive surgeons carry no such area limit, and a specialised physician is restricted instead to the anatomy their own licensed title covers. Abu Dhabi is also the only one of the two standards that recognises oculoplastic surgery, the specialty that owns this anatomy, as a category at all.
Same country, same treatment, a genuinely different rule about who may hold the needle. That is worth knowing before you book, and it is worth knowing that neither position is careless. They are two regulators reaching different conclusions about the same square inch.
For context on how the American regulator handled it: when one filler was approved for under-eye hollowing in 2022, the manufacturer says it was required to run a training programme covering the anatomy and complication management of the area, and completion was a condition of using the product for that indication. Dubai's standard imposes no site-specific training requirement for the eye. That is an observation about two regulators, not about any injector's competence.
Needle or cannula, which is a safety question
No Dubai page we read treats the choice of instrument as anything other than a preference. The evidence says otherwise.
In that 1.7-million-syringe dataset, cannula injections carried 77.1 per cent lower odds of occlusion than needles, roughly six times fewer events per syringe. Cadaver work explains the mechanism: a blunt cannula kept the product confined to the deep layers, while a sharp needle placed material across multiple planes and produced intra-arterial injection even with the tip resting on bone. In one comparison, injections with a needle changed plane 60 per cent of the time and injections with a cannula never did.
The correction, which matters as much: a cannula lowers the odds, it does not remove them. Arterial wall penetration remains possible with the wrong plane, too much pressure or poor anatomical control, and a 2026 review notes that publication bias probably understates true complication rates for both instruments. Experience counts too. In the same large dataset, injectors with more than five years of filler experience had 70.7 per cent lower odds of an occlusion.
The money, and the number nobody prints
PUBLISHED UAE MENUS
Those are only the pages that publish a real low and a real high. Plenty do not. Several quote a starting figure with no ceiling, one prices by the unit so the total depends on how much is used on the day, one runs a discount against its own unaudited comparison price, and one manages to publish two different floors on the same page. Two clinics publish different prices for the same treatment on different pages of their own site. We have not blended any of this into a single market range, because no source states one.
BEFORE YOU BOOK
VAT
5 per cent
- Stated on
- Two of the eighteen pages we read, both saying prices exclude it
- Everywhere else
- Silent, so you cannot tell whether the figure is inclusive
The second syringe
Often needed
- What the pages say
- One to two syringes typical, assessed at consultation
- The effect
- A one-syringe headline is not a two-syringe quote
The top-up
Sooner than the material leaves
- The claim
- Six to twelve months is the modal Dubai figure
- The research
- One retrospective study of 155 patients found effect still present at eighteen months
Taking it out
AED 200 to AED 2,000
- Where we found prices
- Seven Dubai clinic pages openly selling hyaluronidase dissolving
- Where we did not
- Any of the eighteen under-eye treatment pages
Surgery, if filler was the wrong answer
On no menu we read
- The evidence
- In one series of 54 people who had periorbital filler dissolved, 64.8 per cent went on to lower eyelid surgery
- The caveat
- A referral centre seeing established complications, so heavily selected. Not a general risk figure
A separate series of 48 patients who had gone on to want lower eyelid surgery after under-eye or cheek filler found that 83.3 per cent showed evidence of at least one filler-associated adverse effect, a third of them presenting more than three years after the injection and another third unable to recall when it had been. That is also a selected group, for the same reason.
That last card needs its caveat read as carefully as its number. Those 54 people had all gone to a specialist because something had gone wrong, and they presented on average more than two years after their first injection. It does not mean two thirds of tear trough patients end up in an operating theatre. It does mean that once this treatment goes wrong in a way that needs undoing, dissolving is frequently not the end of the story. For how per-syringe pricing works across the rest of the face, we have covered dermal filler costs in Dubai separately.
A consultation that does not name which of the four problems you have has skipped the only step that decides whether the money works.
When the answer is no
The clearest published account of who should not have this comes from that same manufacturer-funded 2023 review, and it is mostly about structure rather than preference. Prominent or herniated fat pads, because filler cannot camouflage a contour that is bulging forward. Significant skin laxity. A hypertrophied muscle producing a roll under the lash line, where the hollow sits in a place that is difficult to inject and where treatment tends not to work. Any history of fluid retention or existing eyelid or malar swelling, since that is the complication you are most likely to provoke. Prominent malar mounds or festoons.
Add the things that are not hollowing at all: surface pigment, deep pigment associated with venous congestion, fine lines casting their own small shadows, and translucent skin through which the muscle simply shows. Filler treats none of them. If skin quality is the real problem, skin boosters and biostimulators are a different conversation, and so is the pigment route.
Dubai's standard adds one flat rule: cosmetic botox and fillers are not permitted for patients under eighteen. Abu Dhabi's adds two requirements Dubai's does not. Procedures may not be performed on pregnant patients, stated absolutely. And a practitioner must ask whether another healthcare professional has already declined to treat you, must screen for body dysmorphic disorder using a validated tool, must consider whether you are seeking treatment to please someone else, and must decline if the procedure is not in your interests. Those are unusually humane clauses and they are worth knowing exist.
Common questions
How much is tear trough filler in Dubai?
On pages that publish a genuine range, roughly AED 1,200 to AED 3,000 per syringe or session, with several topping out at AED 3,500 or AED 4,000 and above. One clinic prices by volume, at AED 800 to 1,100 for half a millilitre on one side and AED 1,500 to 2,200 for a millilitre per side across both eyes. Lower headline figures are generally discounted, open-ended or contradicted elsewhere on the same page.
Can under-eye filler cause blindness?
Filler anywhere on the face can, through an artery. It is rare, rare enough that a UK expert panel declined to put a number on it. The published cases are dominated by the nose, the area between the brows and the forehead. The tear trough does not appear in the top-risk list of any of the three major reviews.
Will filler get rid of my dark circles?
Only if the shadow is caused by hollowing. It will not lighten pigment, and it will not hide vessels showing through thin skin. Dim the room to test for a structural shadow, use bright light and stretch the skin to test for pigment.
Why do my eyes look puffy afterwards?
Swelling is the commonest reported side effect, pooled at 19.2 per cent across 2,556 patients. Some of it settles in days. Some of it does not: one ultrasound study found malar oedema starting anywhere from immediately to three years after treatment, with the authors concluding the swelling may be caused by filler compressing lymphatic and venous drainage.
What is the blue tinge under my eyes?
The Tyndall effect, from gel placed too superficially under very thin skin scattering light. Pooled at 0.9 per cent. It does not fade usefully on its own and generally needs dissolving.
How long does it last?
Clinics say six to twelve months. One retrospective study of 155 patients found effect still present at eighteen. A small MRI study of fourteen patients found more volume present than had been injected. Treat the clinic's figure as how long the look lasts, not as when the material leaves.
Can it be dissolved, and what does that cost?
Yes, if it is hyaluronic acid. Published Dubai prices run from AED 200 per millilitre to AED 700 to 2,000 per session. Note that calcium hydroxylapatite and poly-L-lactic acid fillers, which some Dubai pages offer for the under-eye on longevity grounds, are not dissolvable this way. Dissolving is also not free of consequence. Reported allergic reaction rates run from 0.05 to 0.7 per cent, the enzyme breaks down your own hyaluronic acid as well as the filler so the area can read more hollow for a period afterwards, and in one series of fifteen women with malar oedema it did not help at all.
Who is allowed to inject it in Dubai?
A trained and privileged licensed physician, or a specialist dentist in orthodontics, prosthodontics or maxillofacial surgery. Fillers are prescription-only, so nurses and beauty therapists may not. In Abu Dhabi, general practitioners and specialty dentists are barred from the eye area entirely.
Cannula or needle?
In the largest dataset available, cannulas carried 77.1 per cent lower odds of vascular occlusion. That is a meaningful difference and a fair question to ask. It does not make a cannula risk-free.
Should I have filler or surgery?
If the problem is a fat pad bulging forward, filler is the wrong tool and a good injector will say so. Filler fills the hollow behind the bag; it does not remove the bag.
What should I ask before booking?
Which of the four causes is producing my dark circles, and how did you decide. Who is injecting, what does their licence say, and are they injecting or supervising. Needle or cannula, and why. Do you keep hyaluronidase on site, and how much. What does it cost to dissolve this if I do not like it.
Sources and methodology
Prices here are indicative 2026 market estimates read from eighteen published UAE clinic pages in September 2026, attributed to the pages that published them and never blended into a market average. Where a source gives an open-ended starting figure we have kept it open rather than inventing a range. Only two of those pages state VAT treatment, both excluding it; the rest are silent, and we have not assumed. Clinical figures are given with their study designs and sample sizes because in this topic the design is the finding: a practitioner survey, a pooled meta-analysis and a review of published cases are three different kinds of evidence. Two of the most detailed clinical sources used here carry manufacturer sponsorship, and we have said so where their conclusions are used. Regulatory clauses are quoted from the official DHA and DoH standards, both downloaded and searched in full text. We review this article periodically and update figures as menus and standards change.
This is informational and is not individual medical advice. Confirm anything specific with a licensed clinic, and with the named physician who would perform the procedure.
- FDA approves Juvederm Volbella XC for undereye hollows, AbbVie, 8 February 2022
- Standards for Non-Surgical Cosmetic Procedures, version 2.1, Dubai Health Authority, effective 18 February 2025
- Non-Surgical Cosmetics Standard, Department of Health Abu Dhabi, effective January 2025
- Consensus guidelines for the management of tissue filler-induced vision loss in the United Kingdom, Aesthetic Surgery Journal 2026
- Alam M et al, Rates of vascular occlusion associated with using needles vs cannulas for filler injection, JAMA Dermatology 2021
- Beleznay K et al, Update on avoiding and treating blindness from fillers, Aesthetic Surgery Journal 2024
- The efficacy and safety of hyaluronic acid injection in tear trough deformity: a systematic review and meta-analysis, Aesthetic Plastic Surgery 2024
- Lower eyelid dark circles: a stepwise assessment framework, Aesthetic Surgery Journal 2024 (Galderma-sponsored)
- Infraorbital hollow rejuvenation: considerations, complications, and the contributions of midface volumization, Aesthetic Surgery Journal Open Forum 2023 (Allergan-funded)
- Treatments of periorbital hyperpigmentation: a systematic review, Dermatologic Surgery 2021
- Classification and characteristics of periorbital hyperpigmentation, Skin Research and Technology 2020
- Arterial anatomy of the tear trough region in Chinese cadavers, Aesthetic Plastic Surgery 2025
- Hyaluronidase use in aesthetic medicine: formulations, safety, and clinical practice, Journal of Clinical Medicine 2025
- Single-session high-dose hyaluronidase for managing periorbital hyaluronic acid filler complications, Aesthetic Plastic Surgery 2026
- Navigating lower eyelid blepharoplasty in patients with under-eye filler, Plastic and Reconstructive Surgery 2025
- Long-term effects of tear trough hyaluronic acid filler: a retrospective study, Journal of Clinical and Aesthetic Dermatology 2025
Clinics in our directory include Altaderma Clinic in Jumeirah, which lists under-eye fillers, and SKIN111 on Palm Jumeirah, which lists dermal fillers and injectables. The wider set is in our injectables and aesthetics category.